Following 2Q results, momentum seems most favorable for the companies below:META (Outperform) - While sentiment was already elevated ahead of the print, 2Q results were strong and guidance for 3Q was encouraging, with expectations for revenue growth ahead of initial St. estimates by ~700bps. Additi
BRT Apartments Corp. Files Second Quarter 2025 Financial Statements GREAT NECK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, announced today that it has filed its quarterly report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that ow...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung – Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 % bei 43 auswertbaren Patienten und eine Gesamtüberlebensrate von 79 % nach 12 Monaten – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln und Barmitteläquivalenten, einschließlich des erfolgreichen Börsengangs mit ei...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités - Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 % et un taux de survie globale de 79 % à 12 mois - D’après le plan d’exploitation actuel de la société, la trésorerie et les équivalents de trésorerie existants, notamment le produit brut de 345 millions de dollars réalisé à l’issue d’une offre publique réussie et les titres négociables devr...
Figure 1. 2Q25 Results vs. EstimatesSource: Company reports, Wedbush estimates, FactSet consensus2Q25 results ahead of expectations. DoorDash reported 2Q marketplace gross order value (GOV) of $24.2B (+23.0% Y/Y) above the Street's estimate of $23.6B (+19.8% Y/Y) and ahead of the high end of guidan
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET. The webcast of the presentation will be conte...
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $345M gross proceeds, and marketable securities expected to fund Merus’ operations at least into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE...
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Co...
Key Findings:US hotel RevPAR growth has averaged -0.4% Y/Y in 2Q, from +2% Y/Y in 1Q and +4% Y/Y in 4Q24. Growth fell ~1% Y/Y in June after flat Y/Y growth (~0%) in both May and April. Trends are slightly more positive on a 2-year stacked basis, with RevPAR growth averaging +1% Y/Y in 2Q, consisten
BRT Apartments Corp. Announces the Acquisition of Apartment Complex in Auburn, Alabama GREAT NECK, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, today announced the acquisition of 1322 North, a 214-unit Class A apartment complex in Auburn, Alabama. The acquisition of 1322 North complements BRT’s ownership of The Village at Lakeside, an Auburn, Alabama property it has owned since 2019. The properties are located one mile from each other and near the region’s two largest employers, Auburn University and East Alabama Medical Center....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.